Exudative vitreoretinopathy 1

Summary

Exudative vitreoretinopathy 1 (MONDO:0007589) is a disease caused by FZD4 (GenCC Definitive), with 7 cohort genes.

At a glance

• Causal gene: FZD4 (GenCC Definitive)
• Cohort genes: 7
• ClinVar variants: 369

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	exudative vitreoretinopathy 1
Mondo ID	MONDO:0007589
MeSH	C536382
OMIM	133780
DOID	DOID:0111412
NCIT	C175048
UMLS	C1851402
MedGen	343561
GARD	0015068
Is cancer (heuristic)	no

Also known as: EVR1 · exudative vitreoretinopathy 1 · exudative vitreoretinopathy type 1

Data availability: 369 ClinVar variants · 5 GenCC gene-disease records · 1 cell line.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal vascular disorder › exudative vitreoretinopathy › FZD4-related exudative vitreoretinopathy › exudative vitreoretinopathy 1

Related subtypes (1): retinopathy of prematurity

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

369 retrieved; paginated sample, class counts are floors:

175 uncertain significance, 70 likely benign, 47 benign, 28 conflicting classifications of pathogenicity, 24 benign/likely benign, 13 pathogenic, 6 likely pathogenic, 5 pathogenic/likely pathogenic, 1 not provided

ClinVar	Variant (HGVS)	Gene	Classification	Review
225170	NM_001904.4(CTNNB1):c.1434_1435insC (p.Glu479fs)	CTNNB1	Pathogenic	no assertion criteria provided
225172	NM_001904.4(CTNNB1):c.2142_2157dup (p.His720Ter)	CTNNB1	Pathogenic	no assertion criteria provided
560087	Single allele	EED	Pathogenic	criteria provided, single submitter
1706535	NM_012193.4(FZD4):c.1273del (p.Thr425fs)	FZD4	Pathogenic	criteria provided, single submitter
1805086	NM_012193.4(FZD4):c.244_245delinsG (p.Phe82fs)	FZD4	Pathogenic	criteria provided, single submitter
1806078	NM_012193.4(FZD4):c.173A>G (p.Tyr58Cys)	FZD4	Pathogenic	criteria provided, single submitter
224624	NM_012193.4(FZD4):c.313A>G (p.Met105Val)	FZD4	Pathogenic	criteria provided, multiple submitters, no conflicts
224625	NM_012193.4(FZD4):c.1282_1285del (p.Asp428fs)	FZD4	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
5484	NM_012193.4(FZD4):c.1479_1484del (p.Met493_Trp494del)	FZD4	Pathogenic	criteria provided, single submitter
5485	NM_012193.4(FZD4):c.1501_1502del (p.Leu501fs)	FZD4	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
5488	NM_012193.4(FZD4):c.1005G>C (p.Trp335Cys)	FZD4	Pathogenic	no assertion criteria provided
1179140	NM_002335.4(LRP5):c.2555C>T (p.Thr852Met)	LRP5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2751235	NM_002335.4(LRP5):c.1372del (p.Leu458fs)	LRP5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
520845	NM_002335.4(LRP5):c.3232C>T (p.Arg1078Ter)	LRP5	Pathogenic	criteria provided, multiple submitters, no conflicts
6269	NM_002335.4(LRP5):c.1282C>T (p.Arg428Ter)	LRP5	Pathogenic	criteria provided, multiple submitters, no conflicts
6274	NM_002335.4(LRP5):c.1481G>A (p.Arg494Gln)	LRP5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
929300	NM_002335.4(LRP5):c.1412+1G>A	LRP5	Pathogenic	criteria provided, multiple submitters, no conflicts
5486	NM_012193.4(FZD4):c.1250G>A (p.Arg417Gln)	PRSS23	Pathogenic	criteria provided, single submitter
2572027	NM_012193.4(FZD4):c.740G>A (p.Arg247Lys)	FZD4	Likely pathogenic	criteria provided, single submitter
929302	NM_012193.4(FZD4):c.964A>T (p.Ile322Phe)	FZD4	Likely pathogenic	criteria provided, single submitter
929301	NM_002335.4(LRP5):c.2585A>T (p.Asp862Val)	LRP5	Likely pathogenic	criteria provided, single submitter
3382395	NM_012193.4(FZD4):c.1051G>C (p.Ala351Pro)	PRSS23	Likely pathogenic	criteria provided, single submitter
4293656	NM_012193.4(FZD4):c.1512G>A (p.Trp504Ter)	PRSS23	Likely pathogenic	criteria provided, single submitter
929303	NM_012193.4(FZD4):c.615del (p.Tyr206fs)	PRSS23	Likely pathogenic	criteria provided, single submitter
143141	NM_012193.4(FZD4):c.205C>T (p.His69Tyr)	FZD4	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
306404	NM_012193.4(FZD4):c.1517A>G (p.Lys506Arg)	FZD4	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
497650	NM_012193.4(FZD4):c.1009C>A (p.His337Asn)	FZD4	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
836786	NM_012193.4(FZD4):c.76C>A (p.Gln26Lys)	FZD4	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
882147	NM_012193.4(FZD4):c.379C>T (p.Arg127Cys)	FZD4	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
882148	NM_012193.4(FZD4):c.84G>C (p.Leu28=)	FZD4	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 7 · Orphanet: 28 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
FZD4	Definitive	Semidominant	exudative vitreoretinopathy 1	7

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
FZD4	Orphanet:891	Familial exudative vitreoretinopathy
FZD4	Orphanet:90050	Retinopathy of prematurity
FZD4	Orphanet:91495	Persistent hyperplastic primary vitreous
ZNF408	Orphanet:791	Retinitis pigmentosa
ZNF408	Orphanet:891	Familial exudative vitreoretinopathy
CTNNB1	Orphanet:1501	Adrenocortical carcinoma
CTNNB1	Orphanet:210159	Adult hepatocellular carcinoma
CTNNB1	Orphanet:2780	Osteopathia striata-cranial sclerosis syndrome
CTNNB1	Orphanet:33402	Pediatric hepatocellular carcinoma
CTNNB1	Orphanet:404473	Intellectual disability-eye abnormalities-microcephaly-peripheral spasticity syndrome
CTNNB1	Orphanet:54595	Craniopharyngioma
CTNNB1	Orphanet:569248	Microcystic stromal tumor
CTNNB1	Orphanet:689430	Adenoid ameloblastoma
CTNNB1	Orphanet:873	Desmoid tumor
CTNNB1	Orphanet:891	Familial exudative vitreoretinopathy
CTNNB1	Orphanet:91414	Pilomatrixoma
CTNNB1	Orphanet:952	Acrofacial dysostosis, Weyers type
EED	Orphanet:659396	Cohen-Gibson syndrome
KIF11	Orphanet:2526	Microcephaly-lymphedema-chorioretinopathy syndrome
LRP5	Orphanet:178377	Osteosclerosis-developmental delay-craniosynostosis syndrome
LRP5	Orphanet:2783	Autosomal dominant osteopetrosis type 1
LRP5	Orphanet:2788	Osteoporosis-pseudoglioma syndrome
LRP5	Orphanet:2790	Endosteal hyperostosis, Worth type
LRP5	Orphanet:2924	Isolated polycystic liver disease
LRP5	Orphanet:3416	Hyperostosis corticalis generalisata
LRP5	Orphanet:498481	LRP5-related primary osteoporosis
LRP5	Orphanet:891	Familial exudative vitreoretinopathy
LRP5	Orphanet:90050	Retinopathy of prematurity

Cohort genes → proteins

7 cohort genes, 7 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	7

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
FZD4	HGNC:4042	ENSG00000174804	Q9ULV1	Frizzled-4	gencc,clinvar
PRSS23	HGNC:14370	ENSG00000150687	O95084	Serine protease 23	clinvar
ZNF408	HGNC:20041	ENSG00000175213	Q9H9D4	Zinc finger protein 408	clinvar
CTNNB1	HGNC:2514	ENSG00000168036	P35222	Catenin beta-1	clinvar
EED	HGNC:3188	ENSG00000074266	O75530	Polycomb protein EED	clinvar
KIF11	HGNC:6388	ENSG00000138160	P52732	Kinesin-like protein KIF11	clinvar
LRP5	HGNC:6697	ENSG00000162337	O75197	Low-density lipoprotein receptor-related protein 5	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
FZD4	Frizzled-4	Receptor for Wnt proteins.
ZNF408	Zinc finger protein 408	May be involved in transcriptional regulation.
CTNNB1	Catenin beta-1	Key downstream component of the canonical Wnt signaling pathway.
EED	Polycomb protein EED	Polycomb group (PcG) protein.
KIF11	Kinesin-like protein KIF11	Motor protein required for establishing a bipolar spindle and thus contributing to chromosome congression during mitosis.
LRP5	Low-density lipoprotein receptor-related protein 5	Acts as a coreceptor with members of the frizzled family of seven-transmembrane spanning receptors to transduce signal by Wnt proteins.

Protein-family classification

Druggable: 3 · Difficult: 2 · Unknown: 2 · Druggable fraction: 0.43

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Protease	1	5.2×	0.682
GPCR	1	3.4×	0.682
Scaffold/PPI	1	2.5×	0.682
Enzyme (other)	1	1.7×	0.685
Transcription factor	1	1.2×	0.714
Other/Unknown	2	0.5×	0.968

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
FZD4	GPCR	yes		Frizzled/Smoothened_7TM, Frizzled/SFRP, GPCR_2-like_7TM
PRSS23	Protease	yes		Trypsin_dom, Peptidase_S1_PA, TRYPSIN_HIS
ZNF408	Transcription factor	no		SET_dom, Znf_C2H2_type, Znf_C2H2_sf
CTNNB1	Other/Unknown	no		Armadillo, ARM-like, Beta-catenin
EED	Scaffold/PPI	no		WD40_rpt, WD40/YVTN_repeat-like_dom_sf, WD40_repeat_CS
KIF11	Enzyme (other)	yes	5.6.1.3	Kinesin_motor_dom, Kinesin_motor_CS, Kinesin-assoc_MT-bd_dom
LRP5	Other/Unknown	no		LDLR_classB_rpt, EGF, LDrepeatLR_classA_rpt

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	7
unknown	0

Top tissues across cohort

Tissue	Cohort genes
ventricular zone	2
adipose tissue	1
right lung	1
subcutaneous adipose tissue	1
mucosa of paranasal sinus	1
nasal cavity epithelium	1
nasal cavity mucosa	1
cervix squamous epithelium	1
endothelial cell	1
tendon of biceps brachii	1
adrenal tissue	1
periodontal ligament	1
endometrium	1
endometrium epithelium	1
lymph node	1
embryo	1
ganglionic eminence	1
ascending aorta	1
mucosa of transverse colon	1
right lobe of liver	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
FZD4	243	ubiquitous	marker	adipose tissue, subcutaneous adipose tissue, right lung
PRSS23	289	ubiquitous	marker	nasal cavity epithelium, nasal cavity mucosa, mucosa of paranasal sinus
ZNF408	224	ubiquitous	yes	endothelial cell, tendon of biceps brachii, cervix squamous epithelium
CTNNB1	295	ubiquitous	marker	adrenal tissue, ventricular zone, periodontal ligament
EED	159	ubiquitous	marker	endometrium epithelium, lymph node, endometrium
KIF11	205	ubiquitous	marker	ventricular zone, ganglionic eminence, embryo
LRP5	224	ubiquitous	marker	right lobe of liver, mucosa of transverse colon, ascending aorta

Protein interactions among cohort

Intra-cohort edges: 4.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CTNNB1	15,668
EED	4,092
KIF11	3,788
LRP5	2,619
FZD4	1,869
ZNF408	1,700
PRSS23	982

Intra-cohort edges

A	B	Sources
FZD4	LRP5	string_interaction
FZD4	ZNF408	string_interaction
KIF11	ZNF408	string_interaction
LRP5	ZNF408	string_interaction

Structural data

PDB: 4 · AlphaFold-only: 3 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
EED	O75530	78
KIF11	P52732	62
CTNNB1	P35222	50
FZD4	Q9ULV1	11

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
PRSS23	O95084	82.18
LRP5	O75197	78.65
ZNF408	Q9H9D4	56.25

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 82. Enrichment computed across 7 evidence-associated genes (6 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Signaling by RNF43 mutants	2	423.0×	7e-04	FZD4, LRP5
Regulation of FZD by ubiquitination	2	173.0×	0.002	FZD4, LRP5
Disassembly of the destruction complex and recruitment of AXIN to the membrane	2	119.0×	0.003	CTNNB1, LRP5
Ca2+ pathway	2	59.5×	0.009	FZD4, CTNNB1
TCF dependent signaling in response to WNT	2	39.2×	0.017	CTNNB1, LRP5
Regulation of PD-L1(CD274) transcription	2	36.2×	0.017	CTNNB1, EED
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production	1	380.7×	0.027	CTNNB1
Signaling by LRP5 mutants	1	271.9×	0.027	LRP5
CDH11 homotypic and heterotypic interactions	1	271.9×	0.027	CTNNB1
Regulation of CDH19 Expression and Function	1	237.9×	0.027	CTNNB1
InlA-mediated entry of Listeria monocytogenes into host cells	1	211.5×	0.027	CTNNB1
Binding of TCF/LEF:CTNNB1 to target gene promoters	1	190.3×	0.027	CTNNB1
RUNX3 regulates WNT signaling	1	190.3×	0.027	CTNNB1
Apoptotic cleavage of cell adhesion proteins	1	173.0×	0.027	CTNNB1
Regulation of CDH11 function	1	173.0×	0.027	CTNNB1
Regulation of CDH1 Function	1	158.6×	0.027	CTNNB1
Formation of axial mesoderm	1	135.9×	0.027	CTNNB1
WNT5A-dependent internalization of FZD4	1	126.9×	0.027	FZD4
Signaling by GSK3beta mutants	1	126.9×	0.027	CTNNB1
CTNNB1 S33 mutants aren’t phosphorylated	1	126.9×	0.027	CTNNB1
CTNNB1 S37 mutants aren’t phosphorylated	1	126.9×	0.027	CTNNB1
CTNNB1 S45 mutants aren’t phosphorylated	1	126.9×	0.027	CTNNB1
CTNNB1 T41 mutants aren’t phosphorylated	1	126.9×	0.027	CTNNB1
Negative regulation of TCF-dependent signaling by WNT ligand antagonists	1	119.0×	0.027	LRP5
Formation of definitive endoderm	1	119.0×	0.027	CTNNB1
Beta-catenin phosphorylation cascade	1	112.0×	0.027	CTNNB1
Germ layer formation at gastrulation	1	112.0×	0.027	CTNNB1
Formation of the nephric duct	1	105.7×	0.027	CTNNB1
Specification of the neural plate border	1	105.7×	0.027	CTNNB1
Signaling by WNT in cancer	1	100.2×	0.027	LRP5

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
establishment of blood-brain barrier	3	601.9×	2e-06	FZD4, CTNNB1, LRP5
extracellular matrix-cell signaling	2	963.0×	1e-04	FZD4, LRP5
Norrin signaling pathway	2	963.0×	1e-04	FZD4, LRP5
establishment of blood-retinal barrier	2	802.5×	1e-04	CTNNB1, LRP5
retinal blood vessel morphogenesis	2	687.8×	1e-04	FZD4, LRP5
canonical Wnt signaling pathway	3	65.7×	4e-04	FZD4, CTNNB1, LRP5
gastrulation with mouth forming second	2	267.5×	8e-04	CTNNB1, LRP5
positive regulation of mesenchymal cell proliferation	2	172.0×	0.002	CTNNB1, LRP5
oligodendrocyte differentiation	2	120.4×	0.003	CTNNB1, EED
embryonic digit morphogenesis	2	86.0×	0.005	CTNNB1, LRP5
glial cell fate determination	1	2407.4×	0.006	CTNNB1
canonical Wnt signaling pathway involved in mesenchymal stem cell differentiation	1	2407.4×	0.006	CTNNB1
cerebellum vasculature morphogenesis	1	2407.4×	0.006	FZD4
cranial ganglion development	1	2407.4×	0.006	CTNNB1
neural plate development	1	1203.7×	0.006	CTNNB1
negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis	1	1203.7×	0.006	CTNNB1
regulation of centriole-centriole cohesion	1	1203.7×	0.006	CTNNB1
progesterone secretion	1	1203.7×	0.006	FZD4
negative regulation of mitotic cell cycle, embryonic	1	1203.7×	0.006	CTNNB1
regulation of timing of anagen	1	1203.7×	0.006	CTNNB1
positive regulation of branching involved in lung morphogenesis	1	1203.7×	0.006	CTNNB1
renal vesicle formation	1	1203.7×	0.006	CTNNB1
renal inner medulla development	1	1203.7×	0.006	CTNNB1
renal outer medulla development	1	1203.7×	0.006	CTNNB1
nephron tubule formation	1	1203.7×	0.006	CTNNB1
regulation of nephron tubule epithelial cell differentiation	1	1203.7×	0.006	CTNNB1
mesenchymal stem cell differentiation	1	1203.7×	0.006	CTNNB1
regulation of adaxial/abaxial pattern formation	1	1203.7×	0.006	EED
positive regulation of determination of dorsal identity	1	1203.7×	0.006	CTNNB1
positive regulation of osteoblast differentiation	2	64.2×	0.006	CTNNB1, LRP5

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 3 · Phased (≥1): 3 · Undrugged: 4

Druggability breadth: 5 of 7 evidence-associated genes (71%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CTNNB1	DITHIAZANINE IODIDE
EED	ASTEMIZOLE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
KIF11	6	3
EED	5	4
CTNNB1	4	4
FZD4	0	0
PRSS23	0	0
ZNF408	0	0
LRP5	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
DITHIAZANINE IODIDE	4	CTNNB1
ASTEMIZOLE	4	EED
TAZEMETOSTAT	4	EED
QUERCETIN	3	CTNNB1
EPIGALOCATECHIN GALLATE	3	EED
GOSSYPOL	3	KIF11
SALINOMYCIN	2	CTNNB1
DALOSIRVAT	2	CTNNB1
POCIREDIR	2	EED
AZD-4877	2	KIF11
LITRONESIB	2	KIF11
ISPINESIB	2	KIF11
FILANESIB	2	KIF11
GSK2816126	1	EED
SB-743921	1	KIF11

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
CTNNB1	361	Binding:358, Functional:3
KIF11	193	Binding:185, Functional:8
EED	176	Binding:170, Functional:6
FZD4	7	Functional:6, Binding:1
LRP5	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
KIF11	5.6.1.3	plus-end-directed kinesin ATPase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CTNNB1	361
EED	176
KIF11	193

Pharmacogenomics

Cohort genes with a PharmGKB record: 7; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

15 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
DITHIAZANINE IODIDE	4	CTNNB1
ASTEMIZOLE	4	EED
TAZEMETOSTAT	4	EED
QUERCETIN	3	CTNNB1
EPIGALOCATECHIN GALLATE	3	EED
GOSSYPOL	3	KIF11
SALINOMYCIN	2	CTNNB1
DALOSIRVAT	2	CTNNB1
POCIREDIR	2	EED
AZD-4877	2	KIF11
LITRONESIB	2	KIF11
ISPINESIB	2	KIF11
FILANESIB	2	KIF11
GSK2816126	1	EED
SB-743921	1	KIF11

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	CTNNB1, EED
B	Phased (≥1) drug, not yet approved	1	KIF11
C	Druggable family + PDB, no drug	1	FZD4
D	Druggable family + AlphaFold only, no drug	1	PRSS23
E	Difficult family or no structure, no drug	2	ZNF408, LRP5

Undrugged target profiles

4 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
ZNF408	0	KIF11
FZD4	7	—
PRSS23	0	—
LRP5	1	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.